Pediatr. praxi. 2012;13(5):294-295

Rotavirus gastroenteritis and prevention

MUDr.Jan Smetana, Ph.D.1, doc.RNDr.Vanda Boštíková, Ph.D.1, MUDr.Pavel Kosina, Ph.D.2, prof.MUDr.Roman Chlíbek, Ph.D.1
1 Katedra epidemiologie, Fakulta vojenského zdravotnictví Univerzity obrany, Hradec Králové
2 Klinika infekčních nemocí, LF UK a FN, Hradec Králové

More than 95 % children under 5 years of age are infected at least once with rotavirus gastroenteritis (RVGE). The highest incidence is

given an average age of 6–24 months. The first infection is usually clinically most serious, each other is more moderate. The most common

complication is dehydration, which is more common than in the case of rotavirus negative acute gastroenteritis. Also the risk of

hospitalization for RVGE is higher. Now, there are two live attenuated oral vaccines for specific prevention of RVGE in group of children

older than 6 weeks of age. Vaccination is recommended for all children.

Keywords: rotavirus gastroenteritis, rotavirus, prevention, immunization

Published: November 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Smetana J, Boštíková V, Kosina P, Chlíbek R. Rotavirus gastroenteritis and prevention. Pediatr. praxi. 2012;13(5):294-295.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. World Health Organisation. Global networks for surveillance of rotavirus gastroenteritis, 2001-2008. Weekly epidemiological record, 2008; 83(47): 421-428.
    2. Clark HF, Offit PA, Parashar UD, et al. Rotavirus vaccines. In Plotkin SA, Orenstein WA, Offit PA. Vaccines. 5th ed. Philadelphia: Saunders, 2008: 715-734. Go to original source...
    3. Soriano-Gabarró M, Mrukowicz J, Vesikari T, et al. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J. 2006; 25: S7-11. Go to original source... Go to PubMed...
    4. Van Damme P, Giaquinto C, Huet F, et al. Multicenter Prospective Study of the Burden of Rotavirus Acute Gastroenteritis in Europe, 2004-2005: The REVEAL Study. J Infect Dis. 2007; 195(Suppl 1): S4-16. Go to original source... Go to PubMed...
    5. Diez-Domingo J, Baldo JM, Patrzalek M, et al. Primary care-based surveillance to estimate the burden of rotavirus gastroenteritis among children aged less than 5 years in six European countries. Eur J Pediatr. 2011; 170(2): 213-222. Go to original source... Go to PubMed...
    6. Gleizes O, Desselberger U, Tatochenko V, et al. Nosocomial Rotavirus Infection in European Countries: A Review of the Epidemiology, Severity and Economic Burden of Hospital-Acquired Rotavirus Disease. Pediatr Infect Dis J. 2006; 25: S12-21. Go to original source... Go to PubMed...
    7. Pediatric ROTavirus European CommitTee (PROTECT). The paediatric burden of rotavirus disease in Europe. Epidemiol Infect. 2006; 134(5): 908-916. Go to original source... Go to PubMed...
    8. Bishop RF, Davidson GP, Holmes IH, et al. Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet 1973; 2(7841): 1281-1283. Go to original source... Go to PubMed...
    9. Parashar UD, Bresee JS, Gentsch JR, et al. Rotavirus. Emerg Infect Dis., 1998; 4(4): 561-570. Go to original source... Go to PubMed...
    10. Van Damme P, Giaquinto C, Maxwell M, et al. Distribution of Rotavirus Genotypes in Europe, 2004-2005: The REVEAL Study. J Infect Dis. 2007; 195(Suppl 1): S17-25. Go to original source... Go to PubMed...
    11. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol. 2005; 15(1): 29-56. Go to original source... Go to PubMed...
    12. Murray PR, Rosenthal KS, Kobayashi GS, et al. Medical Microbiology. 4th ed. St. Louis: Mosby, 2002: 826.
    13. Ansari SA, Springthorpe VS, Sattar SA. Survival and vehicular spread of human rotaviruses: possible relation to seasonality of outbreaks. Rev Infect Dis. 1991; 13(3): 448-461. Go to original source... Go to PubMed...
    14. Bresee JS, Glass RI, Ivanoff B, et al. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 1999; 17: 2207-2222. Go to original source... Go to PubMed...
    15. Velázquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med. 1996; 335(14): 1022-1028. Go to original source... Go to PubMed...
    16. World Health Organisation. Rotavirus vaccines: an update. Weekly epidemiological record 2009; 84(51-52): 533-540. Go to PubMed...
    17. Braeckman T, Van Herck K, Raes M, et al. Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J. 2011; 30(Suppl 1): S21-4. Go to original source... Go to PubMed...
    18. Tate JE, Mutuc JD, Panozzo CA, et al. Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006. Pediatr Infect Dis J. 2011; 30(Suppl 1): S30-34. Go to original source... Go to PubMed...
    19. Cabrnochová H, Skibová J. Proočkovanost dětské populace v České republice v rámci nepovinného očkování. Vakcinologie 2010; 4(2): 50-54.
    20. Centers for Disease Control and Prevention. Statement Regarding Rotarix(R) and RotaTeq(R) Rotavirus Vaccines and Intussusception. 2010, http://www.cdc.gov/vaccines/vpd-vac/rotavirus/intussusception-studies-acip.htm.

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.